Health
Scientific Committees
Scientific Steering Committee (former MDSC)
Outcome of discussions
Minutes of the
Scientific Steering Committee Meeting of 18-19 February
1999
1. Welcome, apologies, introductory remarks,
declaration of interest in relation to the current
agenda
Prof.Dr.Pascal welcomed the
participants. Apologies were received from
Prof.Dr.A.Osterhaus (for 19.02.99), Prof.Dr.K.Jones (for
18.02.99), Prof.Dr.V.Silano, Prof.Dr.P.James and
Prof.Dr.R.Kroes. The list of participants is attached as
annex 1.
No member declared an interest in any of
the point of the agenda which could conflict with his
independence.
2. Approval of the agenda
The draft agenda was slightly modified
and approved. It is attached as annex 2.
3. Approval of the minutes of the meeting of 21-22
January 1999.
The draft minutes of the meeting of
21-22 January 1999 were approved without changes.
4. Work plan for the SSC
4.1. Progress on multidisciplinary matters:
a.
"Considerations for the evolution of scientific advice
to address emerging health issues".
Prof.Dr.W.Klein reported on the Working
Group meeting which was held on 17 February 1999. A task
distribution was agreed upon between the members, along the
lines of the mandate described in the minutes of the 10-11
December 1998 meeting. Further progress will be reported on
at the March meeting.
b.
Harmonisation of risk assessment procedures
No progress was made. Three Scientific
Committees have now provided their contributions. A draft
document will be prepared also on the basis of the
contributions from the secretariats, for discussion by the
working group on 17 March 1999.
The possible enlargement of the mandate
as to include a case study on harmonised risk assessment
procedures for GMOs (ref.: SSC meeting of 21-22 January
1999), will also be discussed at that occasion.
c.
Resistance to antimicrobials
The rapporteur provided the SSC with a
feed-back from the WG meeting of 16 February 1999 and on
the way it is responding to the SSC's suggestions on the
draft report presented on 21-22 January 1999. Contributions
- including on the implications for the environment of the
use of antimicrobials - were received from several SSC
members. The draft report is being finalised. It is
expected to have the final draft report and draft opinion
available for discussion at the SSC meeting of 22-23 April
1999.
4.2. Multidisciplinary matters relating to TSE/BSE
a.
General report of the work of the TSE/BSE ad-hoc
group.
Prof.Dr.M.Gibney, chairman of the
TSE/BSE
ad hoc Group, provided a summary report on the
activities of the Group since last meeting. For most issues
presented by Prof.Gibney, the corresponding details are
provided in Section (b) hereafter.
b.
Reports on specific issues:
b.1. "Fallen stock": The risk of
infectious agents or non conventional transmissible agents
entering the human food or animal feed chains via raw
material from fallen stock, exotic/zoo animals, fur
animals, dead animals, condemned materials, dead fish sick
animals and laboratory animals and including the
environmental aspects of disposal of potentially BSE
infected materials and animals
Prof.Dr.M.Vanbelle, rapporteur of the
Working Group "Producst" reported on the progress made by
the Working Group since its meeting of 15 December 1999 and
on the (present) general content of the draft report. He
confirmed that a draft opinion would be ready for
discussion by the SSC at its meeting of March 1999.
A short discussion was held and
suggestions were made towards the Working Group. These will
be discussed at the next WG meeting of 24 February
1999.
b.2. Intra-species recycling of animals
waste.
A draft report has still not been
adopted by the WG. It is now expected that a draft will be
available for discussion by the SSC at its meeting of 18-19
March 1999.
b.3. Safety of gelatine (update of the
opinion of 26-27 March 1998)
The opinions on the safety of hydrolysed
proteins (adopted on 23-24.10.98) and on the possible use
of the "133°C/20'/3 bars" production standard (see previous
section) contain a number of conclusions which have also
implications for the opinion on the Safety of gelatine,
adopted on 26-27 March 1998. The latter opinion needed
therefore to be updated to take into account also the use
of hides from healthy animals and the possible use of the
"133°C/20'/3 bars" production standard.
The opinion also needed minor updates so
as to include the final report on the INVERESK inactivation
study, which became only available after the
adoption.
An updated draft opinion was presented
and adopted It is attached as Annex 3.
b.4. The possible vertical transmission
of Bovine Spongiform Encephalopathy.
The Working Group finalised its report
and an initial version of a draft opinion has been
prepared. However, no consensus has been reached so far on
the exact formulation of a number of conclusions. An
additional meeting of the working group has therefore been
scheduled for 4 March 1999. Following discussion by the
TSE/BSE
ad hoc Group on 11 March, the discussion and
possible adoption of the opinion is therefore now scheduled
for the SSC meeting of 18-19 March 1999.
b.5. Safety of tallow derived from bones
as a by-product in the gelatine production.
On request from DGVI, the SSC is
addressing the issue of the safety with respect to TSE
infectivity of tallow derived from bovine bones as a
by-product of the gelatine production. The specific hazards
are linked to the fact that such tallow seems to be
processed according to lower standard than the "133°C/20'/3
bars" conditions defined by the SSC in its opinion on
meat-and-bone meal and to the possible presence of the
vertebral column in the raw material.
The Working Group has carried out a
quantitative risk assessment and an opinion will be drafted
by the TSE/BSE ad hoc Group and submitted to the SSC at its
meeting of March 1999.
b.6 Human exposure risk (HER).
The SSC was informed on the progress
made and requested the TSE/BSE ad-hoc group to closely
follow this important matter.
b.7. Safety of blood: feed back from the
Scientific Committee Medicinal Products and Medical Devises
(SC-MPMD) following the Hill
et al paper (Lancet, 1999,
353: 183-189).
Following the request of the SSC
(January 1999 meeting), the SC-MPMD evaluated the Hill
et al paper in detail. The study seems to
demonstrate clearly that the promoting role of B
lymphocytes does not depend on the production of PrP
c, a general prerequisite for the multiplication
of TSE agents. Therefore, it seems less probable that
lymphocytes carry directly TSE infectivity. This finding
has already been discussed in the SC-MPMD opinion of
October 1998. The new findings shed some additional doubts
on the usefulness of leukodepletion. It is expected that
further sudies will focus on the role of the follicular
dentritic cells in pathogenesis. The question as to how the
TSE agents reach these cells have to be addressed.
An opinion is expected to be adopted by
the SC-MPMD at its March meeting.
b.8. Safety of skins: feed back from the
Scientific Committee Medicinal Products and Medical Devises
(SC-MPMD) following the Pammer
et al paper (American Journal of Pathology, 1998,
153: 1353-1358).
Following the request of the SSC
(December 1998 meeting), the SC-MPMD evaluated the Pammer
et al paper on human keratinocytes expressing
cellular prion-related proteins in vitro and during
inflammatory skin disease. In summary, Pammer
et al unequivocally demonstrate the presence of PrP
c in the skin. By this finding, they extent the
range of tissues known to express PrP
c. The majority of observations seems to support
the opinion that skin does not contain TSE infectivity in
significant amounts. However, as there are still some open
questions there is the need for studies investigating the
presence of PrP
Sc, the pathologic form of the prion protein, in
the skin. The methods are easily available. Until those
studies are completed, there is no sound justification for
a change in policy regarding the use of hides and skins for
the preparation of gelatine.
An opinion is expected to be adopted by
the SC-MPMD at its March meeting.
b.9. Manual for the assessment of
geographical BSE risk (adoption of the final opinion,
integrating also the comments received in January
1999).
The SSC was informed on the comments
received on the preliminary opinion and the modifications
proposed by the WG-"Sourcing", which analysed the comments
and recommended to suppress the semi-quantitative risk
assessment. The WG-"Sourcing" had also brought forward a
clarification for the process to conclude on the
geographical BSE-risk from the propagation risk and the
processing risk, which was supported by the TSE/BSE ad-hoc
group and finally accepted by the SSC. After an intensive
discussion the opinion was finally adopted, integrating the
proposed modifications.
b.10 First discussion of the draft
report and opinion on criteria determining BSE-status
categories, taking account of the geographical BSE-risk,
the human exposure risk and the OIE recommendations.
The SSC discussed on the issue without
arriving at a final conclusion. It accepted, however, the
basic concept that the BSE-status will be established on
the basis of the geographical BSE-risk
and other factors, still to be determined. It asked
the TSE/BSE ad-hoc group to continue the discussion and
provide as soon as possible a discussion paper on the
matter.
b.11 Monitoring of the evolution of the
BSE epidemic in the UK.
The Commission invited the Scientific
Steering Committee to address the following two
questions:
- How does the SSC assess the current and expected
(1999-2004) evolution of the number of BSE cases
(epidemic) in the UK, in the light of the OTMS ("Over
thirty Months Scheme") and of the selective culling
programme. Are the current numbers of cases in line with
the scientific expectations?
- In the light of the confirmed 1998 incidence, is it
necessary to continue OTM Scheme for animals falling
under the Date Based Export Scheme
The questions will be addressed by the
TSE/BSE ad hoc Group, who will prepare a draft report and
draft opinion for discussion by the SSC.
5. Organisational matters:
No organisational matters were
discussed.
6. Co-ordination:
a. Recombinant Bovine Somatotropine
(BST)
A detailed feed-back was given by the
chairpersons of the SC-Veterinary Measures relating to
Public health (addressing veterinary public health aspects)
and the Scientific Committee Animal Health and Animal
Welfare (addressing the animal health and animal welfare
aspects).
Draft reports of both Committees are in
an advanced stage and it is expected to have the opinions
available by March 1999. It appears that no conflicts exist
between the two reports and the possibility of preparing a
common introduction will be considered. It was confirmed to
provide the SSC with a copy of the opinions immediately
following their adoption.
b. EMEA Notes for guidance on minimising
the risk of transmitting animal spongiform encephalopathy
agents via medicinal products.
Prof.Dr.K.Jones, chairman of the
SC-Medicinal Products and Medical Devises, reported on the
evaluation of the EMEA Notes carried out by his Committee
at its meeting of 10 February 1999 and on the inputs
provided by the TSE/BSE
ad hoc Group at its meeting of 11 February 1999. A
joint paper had been prepared and was, after discussion and
amendments, also adopted by the SSC. It is attached as
Annex 5.
c. reports of the Chairmen of the 8
Scientific Committees.
The chairmen of Scientific Committees
reported on the activities of their committees since the
last SSC meeting (21-22 January 1999). A summary of their
reports is given in annex 6.
7. Information by the Commission services on matters
related to consumer health.
Due to a lack of time, this agenda item
was postponed until the next meeting.
8. Any other business
-M Rateau (Commission) informed the SSC
on the "European Day of the Consumer" which will be held on
15 March 1999. The day is organised by the Economic and
Social Committee (ECOSOC), in collaboration with the
European Commission. Venue is the headquarters of the
ECOSOC, 2 rue Ravenstein, 1000 Bruxelles. The conference
will start at 14h30' and last until 18h00'. The programme
and additional information will be sent by ECOSOC to all
the SSC members.
- Internal SSC seminar on molecular
biology, neuropathology and testing for prion-related
diseases.
Due to a lack of time, the TSE/BSE
ad hoc Group did not discuss this item at its
meeting of 11 February. It was therefore postponed until
the next meeting.
- Monitoring by the SSC of ongoing
research in the field of TSEs
The secretariat raised this issue and
was supported by the SSC as to its usefulness. However,
questions were raised concerning the capacity of the
secretariat and the TSE/BSE ad-hoc group to organise that
additional task. DG XII signalled that it is reflecting on
providing access to interim reports but that there are
legal problems which are not yet solved.
- Exploitation of scientific
opinions
A preliminary discussion was held on the
exploitation by the Commission of scientific opinions
adopted by its Scientific Committees. No conclusions were
drawn, but it was decided to continue the discussion at a
next SSC meeting.
The meeting ended on Friday 19 February
1999, at 13h30.
The next meeting will be held in
Brussels, on 18-19 March 1999.
Annex 1: List of participants of the Scientific
Steering Committee meeting of 18-19 February 1999
List of presence
Members of the SSC:
Prof. Georges Bories, Prof. W.Bridges
(not present on 18 February morning), Prof. F.Garrido
Abellán, Prof. Michael J. Gibney, Prof. Anthony Hardy,
Prof. Philip James (not present), Prof. Keith H.Jones (not
present on 18 February), Prof. Fritz H.Kemper, Prof. Fritz
H.Kemper, Prof. Werner Klein, Prof. Ib Knudsen, Prof.
Robert Kroes (not present), Prof. Albert Osterhaus (not
present on 19 February), Prof. Gérard Pascal, Prof. Marcel
Vanbelle, Prof. Martin Wierup
Participants from the Commission:
DG III: M.P. Darchy, A. North, O. Rothe, Mr
Silva
DG V H. Buchow
DG VI T. Chalus, M. Lahrssen, C. Micmacher, I.
Peutz, L. Terzi
DG XI V. Matzeit
DG XII A. Fabre
DG XXIV: S. Clarke, J. Costa David, T. Daskaleros,
W. De Klerck, M. de Sola, C.Diez, J.Kreysa, M. Lauridsen,
G.Morrison, J.J. Rateau, A. Sanabria, W. Schuller, A.
Somogyi, R. Vanhoorde, J. Vergnettes, P.Vossen
Annex 2:
agenda of the Scientific Steering Committee Meeting of
18-19 February 1999
1. Welcome, apologies, introductory
remarks, declarations of interest
2. Approval of the agenda
3. Approval of the minutes of the
meeting of 21-22 January 1999.
4. Work plan for the SSC
4.1. Progress on multidisciplinary
matters:
a. "Considerations for the evolution of
scientific advice to address emerging health issues"
(progress report)
b. Harmonisation of risk assessment
procedures (progress report)
c. Resistance to antimicrobials
(feed-back from the WG)
4.2. Multidisciplinary matters relating
to TSE/BSE
a. Report by the chairman of the TSE/BSE
ad-hoc group.
b. Reports on specific issues:
Production systems and products.
b.1. "Fallen stock": The risk of
infectious agents or non conventional transmissible agents
entering the human food or animal feed chains via raw
material from fallen stock, including environmental aspects
of disposal of potentially BSE infected materials and
animals (introduction of the draft report).
b.2. Intra-species recycling of animal
waste (introduction of the draft report).
b.3. Safety of gelatine (adoption of the
update of the opinion of 26-27 March 1998).
b.4. The possible vertical transmission
of Bovine Spongiform Encephalopathy (progress
report)
b.5. Safety of tallow derived from bones
as a by-product in the gelatine production (progress
report).
Human exposure risk.
b.6. First discussion of the draft
report and opinion.
b.7. Safety of blood and skins: feed
back from the Scientific Committee Medicinal Products and
Medical Devises following various Lancet papers.
Geographical risk.
b.8. Handbook for the assessment of
geographical BSE risk (adoption of the final opinion,
integrating also the comments received in January
1999).
b.9 First discussion of the draft report
and opinion on criteria determining BSE-status categories,
taking account of the geographical BSE-risk, the human
exposure risk and the OIE recommendations.
b.10 Monitoring of the evolution of the
BSE epidemic in the UK.
5. Organisational matters.
6. Co-ordination:
a. Recombinant Bovine Somatotropine
(BST): progress reports from the Scientific Committees
Veterinary Measures related to Public Health and Animal
Health and Welfare.
b. Briefing on the Commission's
activities related to hormones.
b. EMEA Notes for guidance on minimising
the risk of transmitting animal spongiform encephalopathy
agents via medicinal products.
c. reports of the Chairmen of the 8
Scientific Committees.
7. Information by the Commission
services on matters related to consumer health.
8. Any other business.
- internal SSC seminar on molecular
biology, neuropathology and testing for prion-related
diseases.
Annex 3:
Scientific Report and Opinion on
The Safety of gelatine
adopted by the Scientific Steering Committee at its
meeting of 18-19 February 1999
Version updated at the SSC meeting of 18-19 February
1999, following the adoption of the following
opinions:
- The safety of hydrolysed proteins produced from
bovine hides (22-23.10.98).
- The safety of bones produced as by-product of the
Date Based Export Scheme. (22-23.10.98)
- Evaluation of an alternative process for the
production of gelatine regarding its equivalency with
commonly used industrial gelatine production processes in
terms of its capacity of inactivating/eliminating
possible TSE infectivity in the raw material.
(22-23.10.98)
- Evaluation of the
"133°/20'/3 bars heat/pressure conditions"
for the production of gelatine regarding its equivalency
with commonly used industrial gelatine production processes
in terms of its capacity of inactivating/eliminating
possible TSE
infectivity in the raw material.
(21-22.01.99)
(This annex was distributed
separately)
Annex 4:
Opinion of the Scientific Steering Committee on a
method to assess the Geographical BSE-risk (GBR) of
countries or regions. Adopted on 18-19 February 1999.
(This annex was distributed
separately)
Annex 5:
Comments on:
1. The EMEA Committee for Veterinary Medicinal
Products: Draft Note for Guidance for minimising the risk
of transmitting animal spongiform encephalopathy agents
via veterinary medicinal products
2. The EMEA Committee for Proprietary Medicinal
Products: Draft Note for Guidance for minimising the risk
of transmitting animal spongiform encephalopathy agents
via medicinal products
Formulated by the Scientific Committee for Medicinal
Products and Medical Devices (SC-MPMD) at its meeting of
10.02.99 and by the Scientific Steering Committee (SSC)
at its meeting of 18-19.02.99, following consultation of
the TSE/BSE ad hoc Group.
The SC-MPMD and the SSC consider that
the EMEA Guidances for minimising the risks of transmitting
animal spongiform encephalopathy agents largely comply with
conditions for safe sourcing, removal of specified risk
materials, appropriate production processes, intended
end-use or application, avoidance of cross-contamination,
etc., listed in the various TSE-related scientific opinions
adopted since November 1997 by the European Commission's
Scientific Committees. (See attached list).
However, the Committees wish to point at
the following sections in both Notes, which are considered
to be open for possible misinterpretation or which need to
be further elaborated in detail:
a.
Regarding the collection of source materials. The
documents consider that the substitution of ruminant source
materials by material from other species which are
recognised to suffer from TSEs,
other than as a result of experimental challenge,
would not normally be acceptable.
The SC-MPMD and the SSC consider that
precautions should be taken to possibly exclude sourcing
from animals that that in practice may have been exposed to
TSE infectivity, for example via feed, and are
experimentally susceptible to TSEs. For most, if not all,
of such animal species, a TSE-specific surveillance system
does indeed not exist, and they can not therefore
automatically be considered as "safe".
b.
Regarding the geographical sourcing of the animals.
The SC-MPMD and SSC recommend that in the criteria
referring to imports of animal materials and to feeding
practices, a time component be introduced, specifying since
when certain imports or feeding practices should have been
banned. The SC-MPMD and the SSC consider that, in order to
be fully effective, these bans should have been enforced
for a period which is at least equal to 8 years. (8 years
corresponds with the upper end of the BSE incubation
period).
c.
Regarding process validation, the SC-MPMD and the
SSC wish to point at the fact that, in all their opinions
related to the safety of bovine derived products, they have
emphasised on the need that the [expected, claimed,
assumed] infectivity reduction capacity of production
processes be validated by appropriate experiments. In the
absence of the results of such experiment(s), and if the
intended end-use implies direct human consumption, it may
even be recommendable not to acknowledge certain production
processes as resulting in an acceptable level of clearance
of infectivity, even if they look similar to other
processes for which such experiments have been carried
out.
d.
Regarding the age of animals. The Notes recommend
sourcing from young animals, because clinical TSE has not
been diagnosed in young animals. Whilst recognising that it
is for the time being difficult to exactly specify the age
of animals which could be safely sourced, the SC-MDMP and
SSC recommend that, for ruminants, the age should be fixed
at 30 months for bovines and at 12 months for ovines and
caprines.
e
Regarding the conditions which should apply to
gelatine, the SC-MPMD and SSC recommend that the
conditions listed in the SSC opinion on the Safety of
Gelatine, adopted on 26-27 March 1998 and amended on 18-19
February 1999 (sections related to the production of
gelatine and to its end-use in registered pharmaceutical
products, for parenteral use and as a reagent in the
manufacture of pharmaceuticals), should also be specified
in detail in the Notes for Guidance.
f. Footnote (9) referring to the
sourcing of bovine bones for the production of gelatine,
would need to be further clarified.
Scientific justifications: sources
The above statements are resulting from
the exploitation of the following scientific opinions
adopted by the Scientific Committee Medicinal Products and
medical Devices and the Scientific Steering
Committee:
- Listing of Specified Risk Materials: a
scheme for assessing relative risks to man (SSC, 9 December
1997)
- Opinion of the Scientific Steering
Committee on defining the BSE risk for specified
geographical areas (SSC, 22-23 January 1998)
- Final Opinion on the contents of a
"Complete dossier of the epidemiological status with
respect to TSEs". (SSC, 19-20 February 1998)
- Opinion on BSE risk (SSC, 26-26 March
1998)
- Opinion on the Safety of Gelatine
(SSC, 26-26 March 1998, updated 18-19 February 1999)
- Opinion and report on the equivalency
of alternative products to intestines of animal origin for
use as surgical sutures (SC-MPMD, 16 September 1998.
- Opinion on the risk of infection of
sheep and goats with Bovine Spongiform Encephalopathy
agent. (SSC, 24-25 September 1998)
- Opinion on the risk quantification for
CJD transmission via substances of human origin. (SC-MPMD,
21 October 1998)
- Preliminary opinion on a method to
assess the geographical BSE-risk of countries or regions
(SSC, 10-11 December 1998)
- Report and Scientific Opinion on the
evaluation of the "
133°/20'/3 bars heat/pressure conditions" for the
production of gelatine regarding its equivalency with
commonly used industrial gelatine production processes in
terms of its capacity of inactivating/eliminating possible
TSE infectivity in the raw material. (SSC, 21-22 January
1999)
Annex 6: Reports from the secretariats of
Scientific Committees on the major activities and
milestones since the SSC meeting of 24-25 September
1998.
Scientific Committee Food
No plenary sessions of the SC-Food have
been held since the last SSC meeting, hence no new opinions
have been adopted. A number of working groups meetings has
taken place.
Scientific Committee on Plants
After three Working Groups met
concurrently on 3 February 1999, the Scientific Committee
on Plants held its 11
th Plenary Meeting on 4 February at which one
opinion was adopted and discussions progressed on a further
eight drafts.
The opinion adopted was:
Plant Protection Products
- Opinion of the Scientific Committee on
Plants regarding the inclusion of azimsulfuron in Annex I
to Directive 91/414/EEC concerning the placing of plant
protection products on the market.
The Committee is completing draft
opinions on two plant protection products, isoxaflutole and
fenarimol, and a further opinion on the relationship
between the elimination or strong reduction in the use of
plant protection products in the cultivation of fruits and
vegetables and the presence of mycotoxins and heavy
metals.
Plant GMOs
The dossier on a modified starch potato
by Amylogene is being evaluated and questions for further
clarification were addressed to the company. Although a
draft opinion was being prepared on a herbicide tolerant
and insect resistant (Bt) maize from Dekalb, the new
owners, Monsanto, have since withdrawn the application and
work has ceased. Opinions are being written on 3 requests
from Member-States invoking Article 16 (the Safeguard
Clause) on GMO plants. A draft opinion on the proposed
protocol for monitoring European corn borer resistance to
Bt should be adopted at its next Plenary meeting on 4
March.
Scientific Committee on Animal Nutrition (SCAN)
Since the last SSC plenary, the SCAN
plenary met on 25 January.
SCAN adopted an update of the SCAN
opinions of Enzymes on one hand and on Microorganisms on
the other hand.
Some other reports that had been
expected for adoption at the January plenary had to be
postponed to the next plenary.
New questions have been submitted to
SCAN, in particular on copper compound. As such a question
concerns several committees (SCF, SCTEE), SCAN agreed to
involve members of these committees for a better
co-ordination.
Scientific Committee Veterinary Measures relating to
Public Health
The SC-VMPH has been addressing the
following issues:
1. Cooling of carcasses during transport;
In principle the Committee agreed on a
draft report. However, in order to avoid any
misunderstanding, a final draft will be circulated to the
members with a view to its formal adoption at the next
plenary.
2. Working Group on the complementary risk assessment on
the use of hormones.
All members of the Committee agreed with
the composition of the Working Group as well as with its
overall balance.
3.
Bovine Somatotropine (public health aspects);
The Committee discussed the general
concept of the draft report and considered the possible
direct and indirect impact on consumer health with a view
to the adoption of the report at the plenary of 15-16
March. Cross-references to the part of the report that is
addressing animal welfare and animal health aspects were
considered.
4. Revision of ante- and post- mortem inspection
procedures for an alternative inspection system for the
slaughter of pigs;
Substantial progress has been made on
this issue is and it is expected to have a final draft
report available for discussion in plenary in May.
5. Evaluation of microbiological criteria and
temperatures for storage and transport of products of
animal origin intended for human consumption:
- partim microbiological
criteria;
Contrary to earlier planning, an
additional working group meeting will be necessary. It is
foreseen to have the draft report finalised by
April.
6.
Listeria.
A working group including expertise from
the SCF has been set up to address the issue of listeria in
ready to eat food. The first working group meeting is
scheduled for 22 March.
7.
Prevalence and methods of control of
cysticercosis;
The draft report is in a progressed
stage. It is expected to have the final draft report ready
by April.
Scientific Committee Cosmetic and non-Food
Products
Prof. Kemper, the chairman, reported on
the topics dealt with since the last SSC meeting.
One plenary meeting and a series of
Working Parties took place, during which the following
items were discussed:
1. Alternatives to animal testing : further to the
approval of the first alternative methods to animal testing
(in vitro test to assess skin corrosivity and to assess
photo-toxicity) and to the adoption of a status report on
the use of alternative methods to animal testing in the
safety evaluation of cosmetic ingredients or mixture of
ingredients, a press release on the issue has been prepared
and sent to the Cabinet of Mrs Bonino.
Besides its work on 'Alternatives', the
Committee started the updating of its Notes of Guidance for
Testing of cosmetic ingredients for their safety
evaluation. This update concerns mainly the insertion of
the recently adoption opinions concerning the above
mentioned in vitro methods into the notes of
guidance.
2. Hair Dyes : as reported during the previous SSC
meeting, the special task force met from 1 to 4 February 99
and wrote status reports on 40 hair dye files. The
secretariat will now make a first selection to be presented
to the next meeting of the Working Party 'Hair Dyes' of 11
March 99.
An opinion on hydroquinone as a hair dye
constituent was adopted by the plenary.
3. Inventory : the committee adopted a status report
on the inventory. The committee states that the information
given for many entries in the inventory has to be improved
and lists the priorities which must be incorporated in the
1
st update of the inventory as published in
1995.
4. Preservatives, Colorants & Fragrances :
opinions were approved on the use of carbamide peroxide as
a teeth bleaching products and on benzylhemiformal.
An opinion was adopted concerning the
limitation and labelling of chemicals listed in Annex VI (=
preservatives) of the cosmetics directive when they are
used for purposes other than for a preservative
function.
5. UV Filters : 7 opinions on UV filters were
adopted during last plenary meeting of 17.2.99. 3 of these
7 substances were provisionally allowed for use in cosmetic
sun screen formulations. Their adoption implies that no
substances are listed any longer in part 2 (provisionally
list) of Annex VII of the cosmetic directive.
A point was raised by a member of the
committee concerning the safety of sun beds and whether
this issue falls within the field of competence of the
committee. As the Commission replied affirmative, a working
party will be set up to this end.
Scientific Committee for Toxicity, Ecotoxicity and
the Environment
Since the mentioned SSC meeting no CSTEE
meetings took place, the next one foreseen being the
plenary on the 4
th of March 1999.
A. The CSTEE has basically been busy finalising the
opinion on '
Endocrine disrupting chemicals
'. The WG chairman has now confirmed that the final
version of the draft will be sent to the CSTEE secretariat
either Friday, 19
th of February or by early next week (22
February). Copies will be immediately distributed among
CSTEE members for final comments. Adoption is foreseen for
the 4
th of March plenary.
B. Regarding the consultation of the CSTEE on the
subject
'Ground level ozone'
, difficulties in finding a meeting date convenient to
a majority of WG members have prevented the possibility of
holding such a meeting before the next CSTEE plenary. It
was agreed to try and get a draft produced on the basis of
contributions of WG and CSTEE members with a view to it
being presented at the next plenary for a first discussion.
It is unlikely that a final opinion, answering fully the
terms of reference, will be adopted then.
C. Since members received the substantial
documentation package on citrates mentioned in the previous
briefing for the attention of the SSC, no progress has been
made on the subject of the consultation of the CSTEE on '
Substitutes of phthalates in teething rings and other
child care articles intended to be put in the mouth
'. During a M. States meeting (Directive 76/769 on
limitations of the marketing and use of certain dangerous
substances and preparations) organised by DG III and which
took place on the 1
st of February 1999, the understanding was that
more data needs to be collected and that Industry should
collaborate with the Commission and M. Sates to help gather
and provide it. However, since then, no data was made
available to the CSTEE secretariat (it was agreed that DG
III should centralise the receiving of data).
D. The CSTEE secretary has been following
developments on the follow up by the competent Commission
services subsequent to the adoption of a number of opinions
by the CSTEE, namely those on
Tin
,
Arsenic
,
Cadmium
and
Pentachlorophenol
and
Phthalates in toys
.
a) In a meeting of the technical progress committee
for Directive 76/769/EEC, held on the 12
th of February 1999, an adaptation to technical
progress of the directive was voted favourably by qualified
majority. It concerned
Tin organic compounds
,
Pentachlorophenol
and
Cadmium
. The basis of the proposal had been the reports
commissioned by the competent Commission service (DG III),
later peer-reviewed by the CSTEE.
b) On the subject of
Phthalates migration from soft PVC toys and child-care
articles
following the adoption by the CSTEE of its opinion on
the 27
th November 1998, the Commission is still
considering risk management options.
E. The
next CSTEE plenary is confirmed for the 4
th of March 1999.
[
©]
- [
HEALTH] - [
SCIENTIFIC COMMITTEES] - [
SCIENTIFIC STEERING COMMITTEE] -
[
OUTCOME OF DISCUSSIONS]
|